Micheal L.Hebert Ph.D.


San Diego + 1.858.314.1173

Dr. Micheal Hebert focuses his practice on counseling clients on strategies for maximizing intellectual property protection and leveraging such protection in several areas of the life sciences. His practice includes drafting and prosecuting patent applications in genetics, personalized medicine, gene therapy, virology, antibodies, stem cells, pharmaceuticals, and microbiology. Micheal also has extensive experience conducting due diligence research and analysis for freedom-to-operate investigations, patent validity opinions, patentability opinions, and technology licensing. In conducting due diligence research, Micheal is proficient in searching patent databases, nonpatent literature databases, and nucleic/amino acid sequence alignment databases.

Micheal's practice also includes an emphasis on licensing and other commercial transactions in the life sciences. He assists clients in matters relating to transfer of intellectual property rights and collaborations between parties, including drafting and negotiating license agreements and joint development agreements. He also performs due diligence assessments of transactions involving the acquisition and transfer of intellectual property rights.

Prior to joining Jones Day, Micheal was a patent agent and scientific advisor at two international law firms and a postdoctoral fellow at Stanford University in the field of human gene therapy and viral vector development. While at Stanford, he was the recipient of the National Hemophilia Foundation Judith Graham Pool Postdoctoral Fellowship and was awarded a National Research Service Award from the NIH. While earning his Ph.D. at the University of Texas at Houston Health Science Center, Micheal worked in the areas of hereditary neurological diseases, DNA structure, and cellular mechanisms of recombination, repair, and replication.


  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Hookipa Pharma completes $84 million IPOJones Day served as IP counsel in connection with the $84 million initial public offering of Hookipa Pharma Inc. (NASDAQ: HOOK).
  • Kyowa Hakko Kirin and BioWa successfully enforce patent rights on antibody technologyJones Day, on behalf of Japanese life sciences company Kyowa Hakko Kirin Company, Limited ("KHK") and its wholly-owned U.S. subsidiary, BioWa, successfully settled a patent infringement suit over three of KHK's patents that underlie KHK's award-winning POTELLIGENT® technology capable of producing therapeutic antibodies with dramatically improved potency and efficacy.
  • AbbVie successfully faces off with Amgen in patent interference involving buffer-free antibody formulationsJones Day represented AbbVie, Inc. in a patent interference against Amgen, Inc. before the PTAB involving the parties' applications/patents generally related to buffer-free antibody formulations, including formulations to adalimumab, marketed as Humira®.
  • Procter & Gamble sells incontinence brand in Spain and Portugal to Paul Hartmann AGJones Day advised The Procter & Gamble Company in the sale of its 'Lindor' adult incontinence brand in Spain and Portugal to Paul Hartmann AG, a supplier of medical and hygiene products.
  • NGM develops global patent portfolio for beta-klotho antibodiesJones Day represents NGM Biopharmaceuticals, Inc. in the development of a global patent portfolio for antibodies to beta-klotho for the treatment of diabetes and other metabolic disorders.
  • Genomatica enters into licensing and joint development agreementsJones Day represented Genomatica on a range of licensing and joint development agreements with multiple partners worldwide.
  • Hookipa Biotech develops worldwide patent portfolioJones Day assists Hookipa Biotech AG in the development of a worldwide patent portfolio.
  • Genomatica establishes global patent portfolios related to production of more sustainable versions of major chemicals, made from alternative feedstocksJones Day represents Genomatica in the development of a worldwide patent portfolio related to methods of producing high-volume basic and intermediate chemicals from alternative feedstocks, such as sugars and cellulosic biomass, using engineered microorganisms.
  • Genentech builds global patent portfolio for therapeutic antibodiesJones Day managed Genentech Inc.'s global patent portfolio and prosecuted patent applications related to therapeutic antibodies.
  • Speaking Engagements

    • October 2006
      Gene Replacement Therapy for Hemophilia B, National Hemophilia Foundation 58th Annual Meeting
    • June 2006
      Treatment for Hemophilia B using Self-complimentary AAV8 Vectors, American Society of Gene Therapy 2006 Annual Meeting
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.